VaxartVXRT
VXRT logo
Fair Value
US$3.33
Share price15 Dec
US$0.5184.7% undervalued intrinsic discount
Loading
1Y30.77%
7D1.90%

Oral Vaccine Platform And Norovirus Opportunity Will Drive Long Term Upside Potential

Analyst Consensus Target compiles analysts opinions to create narratives on stocks using the Analysts Consensus Price Target, forecasted revenue and earnings figures, as well as the transcripts of earnings calls.

Published
15 Dec 25
Views
258
Not Invested

Fair Value vs Share Price

US$3.33
vs US$0.5184.7% undervalued intrinsic discount
PastFuture-108m148m20152017201920212023202520272028Revenue US$40.7mEarnings US$6.5m
-35%
Revenue growth
16%
Profit margin

Recent News & Updates

No updates

Recent updates

No updates

Stay ahead on Vaxart

  • Fair value estimate changes
  • Narrative and analyst updates
  • Key company announcements

Company analysis

Flawless balance sheet and fair value.

Market capUS$121.8m
PB1.5x
Estimated Growth-79.5%
Dividend YieldN/A
Full analysis

CEO & management

Steven Lo
CEO
4.5yrs
CEO Tenure

A clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform.